CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $3.68B, above the global median of $1.15B
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.54%Above 5Y avg (0.24%)
Annual Rate
DKK 0.41Paid annual
Payout Ratio
22.9%Sustainable
Last Ex-Dividend
Dec 4, 2025
The reported statements, read against the company's own industry.
As of FY2024 (year ended September 30, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
23.55BDKK3.68B · vs all stocks (USD)
Trailing P/E
42.51xvs Medical Devices peers
Revenue (TTM)
6.10BDKK953.32M · vs all stocks (USD)
Profit Margin
7.81%vs Medical Devices peers
Beta
1.39xvs all stocks
52-Week Change
-24.95%vs all stocks
Market Capitalization
23.55BDKK3.68B · vs all stocks (USD)
Enterprise Value
19.94BDKK3.11B · vs all stocks (USD)
Trailing P/E
42.51xvs Medical Devices peers
Forward P/E
24.56xvs Medical Devices peers
PEG Ratio
-1.31xvs Medical Devices peers
Price to Sales (TTM)
3.26xvs Medical Devices peers
Price to Book (MRQ)
3.28xvs Medical Devices peers
Enterprise to Revenue
3.27xvs Medical Devices peers
Enterprise to EBITDA
24.59xvs Medical Devices peers
Gross Margin
60.27%vs Medical Devices peers
Profit Margin
7.81%vs Medical Devices peers
Operating Margin
11.00%vs Medical Devices peers
Return on Assets (TTM)
5.44%vs Medical Devices peers
Return on Equity (TTM)
7.94%vs Medical Devices peers
Revenue (TTM)
6.10BDKK953.32M · vs all stocks (USD)
Revenue per Share (TTM)
22.96DKKUpdated Aug 21, 2026Quarterly Revenue Growth
1.20%vs Medical Devices peers
Gross Profit (TTM)
3.66BDKK571.77M · vs all stocks (USD)
EBITDA (TTM)
1.13BDKK176.01M · vs all stocks (USD)
Net Income (TTM)
477.00MDKK74.50M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-35.60%vs Medical Devices peers
Operating Cash Flow (TTM)
847.00MDKK132.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
281.50MDKK43.96M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4100DKKUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.54%vs all stocks
5-Year Average Dividend Yield
0.24%vs all stocks
Payout Ratio
22.91%vs Medical Devices peers
Revenue
5.39BDKKFY2024 · Sep 30, 2024Cost of Goods Sold
2.19BDKKFY2024 · Sep 30, 2024Gross Profit
3.20BDKKFY2024 · Sep 30, 2024Operating Income
645.00MDKK100.74M · vs all stocks (USD)
Pre-tax Income
300.00MDKKFY2024 · Sep 30, 2024Income Tax Expense
65.00MDKKFY2024 · Sep 30, 2024Net Income
235.00MDKKFY2024 · Sep 30, 2024EBIT
327.00MDKKFY2024 · Sep 30, 2024EBITDA (Income Statement)
1.36BDKKFY2024 · Sep 30, 2024Research & Development
325.00MDKKFY2024 · Sep 30, 2024Selling, General & Administrative
2.23BDKKFY2024 · Sep 30, 2024Non-operating Interest Income
15.00MDKKFY2024 · Sep 30, 2024Non-operating Interest Expense
27.00MDKKFY2024 · Sep 30, 2024EPS (Basic)
0.8800DKKFY2024 · Sep 30, 2024EPS (Diluted)
0.8800DKKFY2024 · Sep 30, 2024Basic Shares Outstanding
266.33MSharesFY2024 · Sep 30, 2024Diluted Shares Outstanding
266.33MSharesFY2024 · Sep 30, 2024Net Income from Continuing Operations
235.00MDKKFY2024 · Sep 30, 2024Preferred Stock Dividends
0.00DKKFY2024 · Sep 30, 2024Operating Cash Flow
-49.00MDKKFY2024 · Sep 30, 2024Free Cash Flow
-250.00MDKKFY2024 · Sep 30, 2024Cash & Cash Equivalents (End of Period)
615.00MDKKFY2024 · Sep 30, 2024Starting Profit (CF Statement)
235.00MDKKFY2024 · Sep 30, 2024Stock-based Compensation
26.00MDKKFY2024 · Sep 30, 2024Other Non-cash Items
11.00MDKKFY2024 · Sep 30, 2024Change in Accounts Receivable (CF)
-40.00MDKKFY2024 · Sep 30, 2024Change in Other Assets/Liabilities
-281.00MDKKFY2024 · Sep 30, 2024Capital Expenditures
-201.00MDKKFY2024 · Sep 30, 2024Net Intangibles (CF)
-88.00MDKKFY2024 · Sep 30, 2024Net Investing Cash Flow
-201.00MDKKFY2024 · Sep 30, 2024Long-term Debt Issuance
0.00DKKFY2024 · Sep 30, 2024Long-term Debt Payments
0.00DKKFY2024 · Sep 30, 2024Net Financing Cash Flow
0.00DKKFY2024 · Sep 30, 2024Shares Outstanding
265.98MSharesUpdated Aug 21, 2026Float Shares
181.30MSharesUpdated Aug 21, 2026% Held by Insiders
0.00%vs all stocks
% Held by Institutions
28.60%vs all stocks
Total Cash (MRQ)
691.00MDKK107.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.63DKKUpdated Aug 21, 2026Total Debt (MRQ)
551.00MDKK86.06M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0903xvs Medical Devices peers
Current Ratio (MRQ)
2.92xvs Medical Devices peers
Book Value per Share (MRQ)
23.19DKKUpdated Aug 21, 2026Total Assets
7.15BDKK1.12B · vs all stocks (USD)
Total Current Assets
2.64BDKKFY2024 · Sep 30, 2024Total Liabilities
1.56BDKKFY2024 · Sep 30, 2024Total Non-current Assets
4.52BDKKFY2024 · Sep 30, 2024Total Non-current Liabilities
501.00MDKKFY2024 · Sep 30, 2024Total Current Liabilities
1.06BDKKFY2024 · Sep 30, 2024Cash & Cash Equivalents
615.00MDKKFY2024 · Sep 30, 2024Accounts Receivable
745.00MDKKFY2024 · Sep 30, 2024Inventory
1.08BDKKFY2024 · Sep 30, 2024Accounts Payable
490.00MDKKFY2024 · Sep 30, 2024Short-term Debt
75.00MDKKFY2024 · Sep 30, 2024Long-term Debt
483.00MDKKFY2024 · Sep 30, 2024Common Stock (Book)
135.00MDKKFY2024 · Sep 30, 2024Retained Earnings
5.31BDKKFY2024 · Sep 30, 2024Total Shareholders' Equity
5.59BDKK873.67M · vs all stocks (USD)
52-Week Low
56.25DKKUpdated Aug 21, 202652-Week High
111.80DKKUpdated Aug 21, 202652-Week Change
-24.95%vs all stocks
Beta
1.39xvs all stocks
50-Day MA
68.25DKKUpdated Aug 21, 2026200-Day MA
75.14DKKUpdated Aug 21, 2026Avg 10-Day Volume
492.16KSharesUpdated Aug 21, 2026Avg 30-Day Volume
550.42KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.79DKKUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $3.68B, above the global median of $1.15BNotable
Market cap (USD): 3,678,183,799.632Global Median: 1,146,734,693.424
Revenue is $953.32M, above the global median of $520.53MNotable
Revenue (USD): 953,322,720Global Median: 520,528,949.311
Levered free cash flow is $43.96M, above the global median of $16.24MNotable
Levered free cash flow (USD): 43,964,670Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Denali Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enliven Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SFP Holdings Co., Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
Digital Information Technologies Corporation
3 interpretationsHigh Retained Earnings With Profitability And EquityMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
CTS Co., Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated